1st Counsel – Lifestyle
Author:
UroGen Pharma Ltd.
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
April 8, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026